Published on : Apr 14, 2016
ALBANY, New York, April 14, 2016: The report discusses the clinical issues, ethical issues, and legal and regulatory issues pertaining to the implementation of non-invasive prenatal testing. Non-invasive prenatal testing has been analyzed in the report with two viewpoints: by revenue and by volume, both for the forecast period from 2011 to 2021.
Non-invasive prenatal tests are carried out on pregnant women for the detection of specific chromosomal aneuploidies from the blood sample. This helps identify women at a high risk of having fetal aneuploidies. As opposed to traditional prenatal screening and diagnosis, non-invasive prenatal testing is safe, accurate, and carries no risk of miscarriage. Thus, the non-invasive prenatal testing market is witnessing a shift from conventional screening methods to non-invasive prenatal testing methods. Technological developments in noninvasive prenatal diagnosis methods have enabled medical professionals and parents of unborn children to take preventive measures in case of high-risk pregnancies to avoid babies with possible birth complications. The safety and efficiency of noninvasive prenatal testing methods are expected to fuel the demand for these tests throughout the forecast period.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=677611
Non-invasive prenatal testing is here to stay, as it looks promising and delivers actionable insights that empower doctors to make critical health decisions. It simply investigates the fetal DNA by a blood test to determine if the baby is at risk of acquiring a chromosomal abnormality, tumors, and many other syndromes. The market for non-invasive prenatal testing is expected to grow owing to the increasing incidents of abnormalities in the chromosomes of newborn children. The increasing cases of women at an advanced age giving birth are also fueling the growth of the global non-invasive prenatal testing market. Furthermore, the availability of advanced screening equipment and the high precision of non-invasive prenatal testing are also encouraging the market’s growth.
The global non-invasive prenatal testing market is segmented on the basis of test type into PrenaTest, Harmony, MaterniT21 PLUS, Verifi, Panorama, BambniTest, InformaSeq, Veracity, IONA Test, Non-Invasive Fetal Trisomy Test (NIFTY), and VisibiliT. Out of these, NIPT has seen enormous growth in the past years, the revenue for MaterniT21 PLUS has decreased, and the growth prospects of Verifi, Harmony, and NIFTY look promising. The report gives the exact figures of the major segments leading the market and also analyzes the challenges faced by the global non-invasive prenatal testing market. A comparative test analysis as well as a market forecast for the coming years have been given in the report in a clear manner.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org